NCT04841096: Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure |
|
|
| Recruiting | 3 | 172 | RoW | A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A1) Glimepiride/Vildagliptin/Metformin, B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (B1) Glimepiride/Vildagliptin/Metformin, (A2) Glimepiride/Vildagliptin/Metformin, A2=Glimepiride / Vildagliptin / Metformin (2 mg/ 50 mg/ 1000 mg), (B2) Glimepiride/Vildagliptin/Metformin, B2=Glimepiride / Vildagliptin / Metformin (4 mg/ 50 mg/ 1000 mg) | Laboratorios Silanes S.A. de C.V. | Type 2 Diabetes | 03/24 | 04/24 | | |
NCT03894228: Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry) |
|
|
| Recruiting | N/A | 1750 | Europe | | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa, Spanish Agency of Medicines and Health Products | Inflammatory Bowel Diseases, Pregnancy | 03/24 | 03/28 | | |
